Richter's Transformation Archives

April 10, 2023

ASH 2022: Dr. Arnon Kater on Subcutaneous Epcoritamab for Richter’s Syndrome

Early results from a phase 1b/2 trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients with Richter syndrome.

March 16, 2023

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome

Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.

February 6, 2023

ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Richter’s Transformation

Our own Dr. Brian Koffman interviewed Dr. Nirav Shah, Associate Professor of Medicine at Medical College of Wisconsin, focusing on hematological malignancies. They discussed the latest results from a clinical trial of pirtobrutinib, a new reversible Bruton tyrosine kinase (BTK) inhibitor, for treating Richter transformation.

November 3, 2022

ASCO 2022: Outcomes Of Richter’s Syndrome In Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Platinum or Anthracycline Based Chemotherapy With or Without a BTK Inhibitor (BTKi)

What follows is our patient-friendly summary of this research: Richter’s syndrome (RS), also known as Richter’s transformation, is a rare complication of chronic lymphocytic leukemia (CLL). It transforms into what is usually an aggressive lymphoma with a dismal prognosis.

August 17, 2022

ASH 2021: Dr. Nitin Jain on Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Richter’s Transformation

We discuss early results from an ongoing study of a triple combination therapy with a PD-L1 checkpoint inhibitor for treating Richter’s transformation.

July 6, 2022

ASH 2021: Dr. Alex Herrera on Atezolizumab in Combination with Immunogenic Chemotherapy for Aggressive B-Cell Lymphomas

Discussion of new results from a phase 1 clinical trial of the atezolizumab plus immunogenic chemotherapy. Atezolizumab is a checkpoint inhibitor that blocks PD-L1, a checkpoint protein found on cancer cells. It is already approved for use in treating certain types of bladder cancers and lung cancers.

June 9, 2022

ASH 2021: Dr. Alexey Danilov on Richter’s Transformation After CAR-T Therapy

and President, interviewed Dr. Alexey Danilov, Associate Director of the Toni Stephenson Lymphoma Center at City of Hope in Duarte, CA. They discussed the development of Richter transformation after chimeric antigen receptor T-cell (CAR-T) therapy.

May 20, 2022

ASH 2021: Dr. Jennifer Woyach on Predicting Development of Richter’s Syndrome After Ibrutinib Treatment

Dr. Mato and Dr. Woyach discusses the results of a study looking at which features might predict the future development of Richter’s syndrome in patients treated with ibrutinib.

July 8, 2021

EHA 2021: Dr. Anthony Mato on Pirtobrutinib (LOXO-305) for Richter’s Transformation in Chronic Lymphocytic Leukemia (CLL)

At the annual meeting of the European Hematology Association (EHA) 2021, our own Dr. Brian Koffman interviewed Dr. Anthony Mato, Director of the CLL Program at Memorial Sloan Kettering Cancer Center. They discussed preliminary results from a clinical trial of pirtobrutinib (formerly LOXO-305) in a subset of patients with

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Richter’s Transformation

ASH 2022: Dr. Arnon Kater on Subcutaneous Epcoritamab for Richter’s Syndrome

ASH 2022: Dr. Christine Ryan on Duvelisib Plus Venetoclax for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Richter’s Syndrome

ASH 2022: Dr. Nirav Shah on Pirtobrutinib for Richter’s Transformation

ASCO 2022: Outcomes Of Richter’s Syndrome In Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Platinum or Anthracycline Based Chemotherapy With or Without a BTK Inhibitor (BTKi)

ASH 2021: Dr. Nitin Jain on Triple Combination Therapy with Venetoclax, Obinutuzumab, and Atezolizumab for Richter’s Transformation

ASH 2021: Dr. Alex Herrera on Atezolizumab in Combination with Immunogenic Chemotherapy for Aggressive B-Cell Lymphomas

ASH 2021: Dr. Alexey Danilov on Richter’s Transformation After CAR-T Therapy

ASH 2021: Dr. Jennifer Woyach on Predicting Development of Richter’s Syndrome After Ibrutinib Treatment

EHA 2021: Dr. Anthony Mato on Pirtobrutinib (LOXO-305) for Richter’s Transformation in Chronic Lymphocytic Leukemia (CLL)

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT